Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation

INTRODUCTION: Opioid use disorder (OUD) is a debilitating and persistent disorder. The standard-of-care treatment is daily maintenance dosing of sublingual buprenorphine (BUP-SL) or oral methadone (MET). Monthly, extended-release, subcutaneous injectable buprenorphine (BUP-XR) has been developed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lowry, Natalie, Cowden, Fiona, Day, Edward, Gilvarry, Eilish, Johnstone, Stacey, Murray, Robbie, Kelleher, Mike, Mitcheson, Luke, Marsden, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Addiction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594511/
https://www.ncbi.nlm.nih.gov/pubmed/36270754
http://dx.doi.org/10.1136/bmjopen-2022-067194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594511/
https://www.ncbi.nlm.nih.gov/pubmed/36270754
http://dx.doi.org/10.1136/bmjopen-2022-067194

Ejemplares similares